Drug intelligence / Profile preview

HRS-6213

Development stage: Phase 2
Lead developer: Hengrui Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

HRS-6213 is a chemically synthesized, investigational radio-imaging agent developed for the diagnosis of **solid tumors** using PET (positron emission tomography) imaging. It is being studied for its ability to provide high-quality images to detect and evaluate tumor presence, extent, and possibly guide treatment decisions. The drug is administered intravenously and is currently undergoing Phase 1/2 clinical trials to evaluate its safety, radiation dosimetry, pharmacokinetics, and diagnostic performance in both healthy volunteers and patients with solid tumors. The agent is being developed by Jiangsu Hengrui Medicine and its related entities[1][2][3][5][6][9].

Brand names: HRS-6213HRS6213HRS 6213
Other names: HRS-6213HRS6213HRS 6213

Beyond the preview

Go deeper on HRS-6213.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-6213.